Selective MPP+ Uptake into Synaptic Dopamine Vesicles: Possible Involvement in MPTP Neurotoxicity

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1993 Jun 1

PMID 8102929

Citations 15

Authors

M Del Zompo

M P Piccardi

S Ruiu

M Quartu

G L Gessa

A Vaccari

Affiliations

Soon will be listed here.

Abstract

1. In the present study we provide evidence for a saturable, Mg2+/ATP- and temperature-dependent, tetrabenazine-, dopamine-, and amphetamine-sensitive uptake of 1-methyl-4-phenylpyridinium ion (MPP+) in synaptic vesicles from mouse striatum. 2. Similarity in the properties of the vesicular uptake suggests that in the striatum dopamine and MPP+ share the vesicular carrier. 3. The presence of MPP+ vesicular uptake in dopamine-rich regions such as striatum, olfactory, tubercles and hypothalamus, as well as its absence in cerebellum, cortex and pons-medulla, suggest that monoamine vesicular carriers differ between highly and poorly dopamine-innervated regions. 4. The restriction of active MPP+ uptake to the dopaminergic regions, which reflects the previously shown distribution of [3H]-MPP+ binding sites in mouse brain membranes, indicates MPP+ as a marker of the vesicular carrier for dopamine in dopaminergic neurones. 5. A role in MPP+ neurotoxicity is suggested for this region-specific, vesicular storage of the toxin.

Citing Articles

Changes in Tyrosine Hydroxylase Activity and Dopamine Synthesis in the Nigrostriatal System of Mice in an Acute Model of Parkinson's Disease as a Manifestation of Neurodegeneration and Neuroplasticity.

Kolacheva A, Alekperova L, Pavlova E, Bannikova A, Ugrumov M Brain Sci. 2022; 12(6).

PMID: 35741664 PMC: 9221104. DOI: 10.3390/brainsci12060779.

Neurorestorative Effects of a Novel Fas-Associated Factor 1 Inhibitor in the MPTP Model: An [F]FE-PE2I Positron Emission Tomography Analysis Study.

Park H, Song Y, Moon B, Yoo S, Lee J, Chung Y Front Pharmacol. 2020; 11:953.

PMID: 32676027 PMC: 7333457. DOI: 10.3389/fphar.2020.00953.

Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice.

Machado V, Zoller T, Attaai A, Spittau B Int J Mol Sci. 2016; 17(2).

PMID: 26821015 PMC: 4783885. DOI: 10.3390/ijms17020151.

CNB-001 a novel curcumin derivative, guards dopamine neurons in MPTP model of Parkinson's disease.

Jayaraj R, Elangovan N, Manigandan K, Singh S, Shukla S Biomed Res Int. 2014; 2014:236182.

PMID: 25025041 PMC: 4083212. DOI: 10.1155/2014/236182.

Whole genome expression profile in neuroblastoma cells exposed to 1-methyl-4-phenylpyridine.

Mazzio E, Soliman K Neurotoxicology. 2012; 33(5):1156-69.

PMID: 22776087 PMC: 3470775. DOI: 10.1016/j.neuro.2012.06.009.

References

Glowinski J, Iversen L . Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 1966; 13(8):655-69. DOI: 10.1111/j.1471-4159.1966.tb09873.x. View

Del Zompo M, Piccardi M, Ruiu S, Corsini G, Vaccari A . Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranes. Brain Res. 1992; 571(2):354-7. DOI: 10.1016/0006-8993(92)90677-2. View

Davis G, Williams A, Markey S, EBERT M, Caine E, Reichert C . Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979; 1(3):249-54. DOI: 10.1016/0165-1781(79)90006-4. View

Heffner T, HARTMAN J, Seiden L . A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav. 1980; 13(3):453-6. DOI: 10.1016/0091-3057(80)90254-3. View

Burns R, Chiueh C, Markey S, EBERT M, Jacobowitz D, Kopin I . A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A. 1983; 80(14):4546-50. PMC: 384076. DOI: 10.1073/pnas.80.14.4546. View

Calne D, Langston J . Aetiology of Parkinson's disease. Lancet. 1983; 2(8365-66):1457-9. DOI: 10.1016/s0140-6736(83)90802-4. View

Heikkila R, Hess A, Duvoisin R . Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 1984; 224(4656):1451-3. DOI: 10.1126/science.6610213. View

Johannessen J, Chiueh C, Burns R, Markey S . Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 1985; 36(3):219-24. DOI: 10.1016/0024-3205(85)90062-1. View

Javitch J, DAmato R, Strittmatter S, Snyder S . Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A. 1985; 82(7):2173-7. PMC: 397515. DOI: 10.1073/pnas.82.7.2173. View

10.

Westerink B, DE VRIES J . On the origin of dopamine and its metabolite in predominantly noradrenergic innervated brain areas. Brain Res. 1985; 330(1):164-6. DOI: 10.1016/0006-8993(85)90020-4. View

11.

Nicklas W, Vyas I, Heikkila R . Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985; 36(26):2503-8. DOI: 10.1016/0024-3205(85)90146-8. View

12.

Ramsay R, SINGER T . Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem. 1986; 261(17):7585-7. View

13.

Barbeau A, Roy M, Bernier G, Campanella G, Paris S . Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci. 1987; 14(1):36-41. DOI: 10.1017/s0317167100026147. View

14.

Scherman D, Darchen F, Desnos C, Henry J . 1-Methyl-4-phenylpyridinium is a substrate of the vesicular monoamine uptake system of chromaffin granules. Eur J Pharmacol. 1988; 146(2-3):359-60. DOI: 10.1016/0014-2999(88)90317-2. View

15.

Erickson J, Masserano J, Barnes E, Ruth J, WEINER N . Chloride ion increases [3H]dopamine accumulation by synaptic vesicles purified from rat striatum: inhibition by thiocyanate ion. Brain Res. 1990; 516(1):155-60. DOI: 10.1016/0006-8993(90)90912-u. View

16.

Johannessen J . A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons. Neurotoxicology. 1991; 12(2):285-302. View

17.

Panagopoulos N, Papadopoulos G, Matsokis N . Dopaminergic innervation and binding in the rat cerebellum. Neurosci Lett. 1991; 130(2):208-12. DOI: 10.1016/0304-3940(91)90398-d. View

18.

Vaccari A, Del Zompo M, Melis F, Gessa G, Rossetti Z . Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine. Br J Pharmacol. 1991; 104(3):573-4. PMC: 1908230. DOI: 10.1111/j.1476-5381.1991.tb12470.x. View

19.

Philippu A, Beyer J . Dopamine and noradrenaline transport into subcellular vesicles of the striatum. Naunyn Schmiedebergs Arch Pharmacol. 1973; 278(4):387-402. DOI: 10.1007/BF00501482. View